Innovotech Inc. (TSX Venture Exchange: IOT; OTCQB: IOTCF) reported financial results for the first quarter ended March 31, 2026, revealing a 44% decline in revenue to $648,140 compared to the same period in 2025. The decrease was primarily driven by a change in activities for a large project with a major customer, which had been anticipated to continue through the year. The company is actively expanding its service offerings and capabilities to generate more consistent recurring revenue and reduce client concentration risk.
Gross profit for the quarter was $202,231, yielding a gross margin of 31.2%, down from 53.6% in the prior year. Margins were negatively impacted by underutilized capacity, as Innovotech maintained staffing and operational readiness in anticipation of the planned customer work. The company recorded a net loss of $401,295 for the quarter, compared to net income of $63,523 in Q1 2025. Operating expenses increased year over year, reflecting the integration of Keystone Labs and Innovotech Labs, the relocation of former Keystone Labs operations to a new facility, and investments in a stronger sales organization.
Despite the challenging quarter, Innovotech continued its strategic transformation, including strengthening its leadership and commercial teams and completing its OTCQB listing in the U.S. The company maintains a strong liquidity position and a meaningful equity base, providing flexibility to manage near-term volatility while executing its longer-term strategy. CEO Craig Milne stated, “Management remains committed to investing in a more diversified, resilient, and scalable platform. The Company is continuing to execute its transformation strategy with a focus on the operational and commercial initiatives required to support long-term growth and reduce revenue concentration risk.”
The company’s unaudited consolidated financial statements and Management’s Discussion and Analysis have been filed on SEDAR+ and the OTCIQ. Innovotech is a life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets. It is a recognized leader in biofilm science and antimicrobial testing, providing advanced laboratory services for medical device, pharmaceutical, and industrial product development. The company operates through ISO-certified and GMP-accredited laboratories and supports clients across multiple sectors, delivering data aligned with regulatory expectations from bodies such as the U.S. Food and Drug Administration and Health Canada. More information is available at https://www.innovotech.ca.
The results highlight the risks associated with customer concentration, as the company's dependence on a major client led to significant revenue volatility. Innovotech's ongoing investments in diversification and commercial capabilities are critical for reducing this risk and achieving more stable financial performance in the future. The company's strong balance sheet provides a buffer as it executes these strategic initiatives.
